CIRIUM
3.9.2024 11:01:28 CEST | Business Wire | Press release
Cirium is now Condor's new partner for aviation analytics, with the new agreement making Cirium the airline’s single source of external aviation data, providing end-to-end data services.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240903082962/en/
Condor A330neo (Photo: Business Wire)
The partnership between Cirium, the aviation analytics firm, and Condor, will empower the German carrier to further improve its operations, driving quality insights aimed at improving the businesses efficiency and overall customer satisfaction.
As part of this new agreement, Cirium will provide the airline with three key data sets: historical flight data, schedules data, and real-time flight data.
Having utilised Cirium's historical flight data for two years, Condor's decision to now integrate Cirium’s additional suite of products presents a unique opportunity to further streamline operations, driving direct improvements for both the business and its customers.
This investment in data will enable the business to swiftly identify operational trends, allowing for quick solutions that reduce costs and enhance efficiency. It will empower teams to optimise fleet management, network planning, connections, and crew scheduling, driving significant improvements across all aspects of operations.
Cirium’s highly regarded flight schedules product is also part of the deal, offering deeper insights into service opportunities and market demand. With the up-to-date data, Condor will be able to optimise network and crew planning, boosting efficiency and profitability across the business.
The addition of Cirium’s real-time flight data will also provide live updates on aircraft around the world, meaning flights can be tracked and monitored with greater detail.
This will support Condor’s investment in its customer experience proposition, with Cirium’s live flight data feeding directly into customer-facing digital platforms, giving travellers precise departure and arrival times so they can plan their onward journeys. The addition of real-time flight data will also transform disruption management, offering even faster rebooking options to those with missed connections.
Jeremy Bowen, Cirium CEO, said: “We are very excited to announce this expanded collaboration with Condor, a leading global leisure airline. Condor has been a client of Cirium, benefiting from our historical flight data, and this strengthened partnership is a testament to both the quality of our data and the dedication of the Cirium team. Through this extended relationship, we will provide Condor with the most precise and reliable industry data, helping them enhance operational performance and, most importantly, deliver timely insights to their passengers worldwide.”
As Germany's most popular leisure airline, Condor has been flying customers to the world’s most beautiful destinations since 1956. With a fleet of over 50 aircraft, the airline serves around 90 destinations from Germany and Switzerland. This partnership with Cirium marks the latest step in Condor’s ongoing commitment to operational excellence and customer satisfaction.
Cirium is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players.
Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com
About Condor
As Germany's most popular leisure airline, Condor has been taking its guests to the world's most beautiful holiday destinations since 1956. Condor operates a fleet of over 50 aircraft, which are maintained by the company's own maintenance operation, Condor Technik GmbH, according to the highest safety standards at the Frankfurt and Dusseldorf locations. In spring 2022, Germany's most popular leisure airline unveiled its new brand identity. This illustrates the development from a leisure airline to a unique and unmistakable vacation brand. The new design was unveiled with the first A330neo, which has been operated by Condor since December 2022. As the German launch customer, Condor will then be flying 21 A330neo long-haul aircraft. Thanks to state-of-the-art technology and maximum efficiency, the latest-generation 2-liter aircraft is the European front-runner with 2.1 liters per passenger per 100 kilometers and maximum customer comfort. Condor will also receive 43 brand-new short- and medium-haul aircraft of the A32Xneo family from 2024.
About Cirium
Cirium® is the world’s most trusted source of aviation analytics, delivering powerful data and cutting-edge analytics to empower a wide spectrum of industry players. Equipping airlines, airports, travel enterprises, aircraft manufacturers, and financial entities, the company provides the clarity and intelligence needed to optimise operations, make informed decisions and accelerate revenue growth.
Cirium® is part of LexisNexis® Risk Solutions, a RELX business, which provides information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
To learn more about Cirium’s products, and how they can benefit your business, visit www.cirium.com, and follow Cirium on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903082962/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
